Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
80°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
77.01
+0.50 (+0.65%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gilead Sciences
< Previous
1
2
...
24
25
26
27
28
29
30
31
32
...
48
49
Next >
7 Penny Stocks That Actually Have a Buy Rating
September 19, 2022
Penny stocks are always a risky proposition. However, investors can still find penny stocks with buy ratings right now.
Via
InvestorPlace
WHO Recommends Gilead's COVID-19 Therapy For Severe Disease
September 16, 2022
Via
Benzinga
Kite’s CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
September 16, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
CHMP Adopts Positive Opinion to Extend Indication of Veklury® (Remdesivir) for the Treatment of Pediatric Patients with COVID-19
September 16, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Why Is Gilead Sciences (GILD) Stock Up Today?
September 12, 2022
Gilead Sciences has a low valuation, but no growth. Perhaps settling a patent lawsuit will help give GILD stock the boost it needs.
Via
InvestorPlace
Gilead's Trodelvy Shows Improved Overall Survival In Pretreated Breast Cancer Settings
September 08, 2022
Via
Benzinga
WHO Expands Recommendation for Veklury® (Remdesivir) to Patients With Severe Disease in Latest Update to COVID-19 Guideline
September 15, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
September 15, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Delayed Generic Entry Is Positive For This Large Pharma's HIV Franchise Sales, Analyst Says
September 15, 2022
Gilead Sciences Inc (NASDAQ: GILD) disclosed agreements with generic manufacturers that delay the U.S. launch of generic TAF products from 2025 to 2031/2032.
Via
Benzinga
Taking Charge of Your Care This Blood Cancer Awareness Month
September 15, 2022
(BPT) - Being empowered often comes from being informed. And when it comes to diseases like blood cancer, having or not having information can make a significant difference in outcomes.
Via
Brandpoint
Topics
Death
Exposures
Death
Kite Pharma's CAR T-Cell Therapy Wins European Approval In Refractory Leukemia Setting
September 07, 2022
Via
Benzinga
Raymond James Initiates AnaptysBio With ~42% Upside, Despite Trial Setback
September 02, 2022
Via
Benzinga
US Department Of Health, Defense To Inject $1B To Boost Domestic Biomanufacturing
September 14, 2022
Via
Benzinga
Biden Administration Pushes 'Cancer Moonshot' Initiative: Report
September 13, 2022
President Joe Biden channeled John F. Kennedy on the 60th anniversary of the former President's moonshot speech, highlighting the Biden administration's efforts to "end cancer as we know it." The...
Via
Benzinga
Gilead Foundation Awards $20 Million to Organizations Working to Advance Health Through Education Equity
September 13, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Why HIV Testing Should Be an Important and Normal Part of Your Self-Care Routine
September 09, 2022
(BPT) - The COVID-19 pandemic introduced unprecedented challenges and altered ways of living across the globe. Now, more than two years later, the effects are still felt widely. Many non-emergent...
Via
Brandpoint
Exposures
COVID-19
Is First Trust Large Cap Core AlphaDEX ETF (FEX) a Strong ETF Right Now?
September 08, 2022
Making its debut on 05/08/2007, smart beta exchange traded fund First Trust Large Cap Core AlphaDEX ETF (ETF:FEX) provides investors broad exposure to the Style Box - Large Cap Blend category of the...
Via
Benzinga
Trodelvy® Significantly Improved Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in TROPiCS-02 Study
September 07, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Kite’s CAR T-cell Therapy Tecartus® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)
September 06, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead's Breast Cancer Drug Improves Progression-Free Survival in HR+/HER2- Metastatic Breast Cancer
September 06, 2022
Via
Benzinga
New TROPiCS-02 Data in HR+/HER2- Metastatic Breast Cancer Patients Demonstrates Progression-Free Survival Benefit of Trodelvy® Regardless of Their HER2 Status
September 04, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Everest Medicines Descends To New Depths On String Of Bad News
September 01, 2022
Key Takeaways: The CEO of Everest Medicines resigned two days after the company announced its loss grew sharply in the first half of the year The company also lost an important potential new revenue...
Via
Benzinga
Gilead Sciences to Present at Upcoming Investor Conferences
August 29, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Demonstrates Strength of Oncology Portfolio Across Diverse Tumor Types at ESMO Congress 2022
August 29, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead's Lenacapavir Scores European Approval For Pretreated HIV Patients After Manufacturing Delays
August 22, 2022
Via
Benzinga
Gilead Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice-Yearly HIV Treatment Option
August 22, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Week In Review: Everest Sells Trodelvy Rights Back To Gilead For $455 Million
August 20, 2022
Shanghai Everest Medicines returned rights for Trodelvy to Immunomedics, now a subsidiary of Gilead Sciences, in an agreement worth up to $455 million ($280 million upfront).
Via
Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
August 19, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Looking For Ebola Virus Meds? WHO Recommends These Two Antibody Treatments
August 19, 2022
Via
Benzinga
Covid Stocks Pfizer, Moderna, Novavax Face Their Next Challenge, And It's Worth Billions
August 19, 2022
How they handle an upcoming shift in payments will be telling for their tailwind.
Via
Investor's Business Daily
< Previous
1
2
...
24
25
26
27
28
29
30
31
32
...
48
49
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.